Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Nephrology | Hepatology (Liver, Pancreatic, Gall Bladder) | Family Medicine
Clinical Trials: Liver Cancer
A listing of clinical trials currently looking for volunteers to enroll in Liver Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : UAB
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
California
Duarte : City of Hope
A Multicenter, Global, Randomized, Double-Blind Study of Axitinib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Following Failure of One Prior Antiangiogenic Therapy
View More »
La Jolla : Moores University of California San Diego Cancer Center
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Los Angeles :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Orange : University of California Irvine Medical Center
TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
San Francisco : California Pacific Medical Center
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Santa Monica :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Stanford : Stanford Hospital and Clinics
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Florida
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Georgia
Savannah : Memorial University Medical Center
AHEP0731: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Liver Cancer
Michigan
Detroit :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Missouri
St. Louis :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Montana
Billings : Billings Clinic
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
New Jersey
New Brunswick : Robert Wood Johnson University Hospital
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
New Brunswick : The Cancer Institute of New Jersey
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
New York
Bronx : Biomedical Research Alliance of New York
Colorectal Liver Metastases Study
View More »
New York :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Ohio
Canton : Gabrail Cancer Center
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Cleveland : University Hospitals Case Medical Center
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Pennsylvania
Philadelphia : Thomas Jefferson University
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Tennessee
Nashville :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Texas
Houston : UT MD Anderson Cancer Center
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Houston : The Methodist Hospital Department of Surgery
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Houston :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Houston : UT MD Anderson Cancer Center
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Houston : UT MD Anderson Cancer Center
Humanitarian Device Exemption (HDE) Treatment Protocol
Washington
Seattle :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
DEFIBROTIDE2006-05 -Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CRF 312.34)
Belgium
Bruxelles :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Gent :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Canada
Edmonton : University of Alberta
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Hamilton : Juravinski Cancer Centre
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Ottawa : Ottawa Hopsital Research Institute
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Vancouver : University of British Columbia
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
China
Shanghai : Fudan University Zhongshan Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
France
Angers :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Clermont-Ferrand : CHU d'Estaing
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Clichy :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Grenoble :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Lyon Cedex : Hôpital de la Croix Rousse
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
View More »
Marseille :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Nice :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Paris :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Strasbourg Cedex : Hôpitaux Universitaires de Strasbourg - Hôpital Civil
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Toulouse : Hôpital Purpan
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Toulouse :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Vandoeuvre-les-nancy :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Villejuif :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Germany
Berlin :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Frankfurt Am Main :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Heidelberg :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Munich :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Tübingen :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Hong Kong
Hong Kong : Queen Mary Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Hong Kong :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Pokfulam :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Italy
Benevento :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Milano :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Padova :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Roma :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Japan
Chuo :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Kanazawa :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Kashiwa :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Sayama :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Tokyo :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
View More »
Yokohama :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Korea, Republic of
Ansan-si : Korea University Ansan Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Busan :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Daegu : Kyungpook National University Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Kyunggi-do :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Pusan : Pusan National University Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
View More »
Pusan : Pusan National University Yangsan Hospital (PNUYH)
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Korea University Guro Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Seoul : Samsung Medical Center
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Seoul : Seoul National University Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Seoul : Severance Hospital,Yonsei University Health System
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Seoul : Asan Medical Center
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
Seoul : Gangnam Severance Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Seoul National University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Seoul St. Mary Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Severance Hospital, Yonsei University Health System
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Samsung Medical Center
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Korea University Guro Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul : Asan Medical Center
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Seoul :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Suwon : Ajou University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Yangsan : Pusan National University Yangsan Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
New Zealand
Auckland :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Singapore
Singapore :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Spain
Barcelona :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Madrid :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Santander :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Zaragoza :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Taiwan
Changhua City : Changhua Christian Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Kaohsiung : Chang Gung Memorial Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Kaohsiung :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Kaohsiung City : E-Da Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Kwei-Shan : Chang Gung Memorial Hospital-Linkou Medical Centre
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
View More »
Taichung : China Medical University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Taichung : Taichung Veterans General Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Taichung :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Tainan : National Cheng Kung University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Tainan :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Taipei : National Taiwan University Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Taipei :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Taipei : Shin Kong Wu Ho-Su Memorial Hospital
Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy
Taipei City : Taipei Veterans General Hospital
A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection
Taoyuan :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
TPE : Chi Mei Hospital, Liouying
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
TPE : National Cheng-Kung University Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
TPE : Taipei Veterans General Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
TPE : National Taiwan University Hospital
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
United Kingdom
Bebington :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
London :
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
